| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5381 | Vanillylidenacetone | Novel osteoclastogenesis inhibitor, preventing ovariectomy-induced osteoporosis in ddY mice |
|
| DCC5382 | Varenicline Dihydrochloride | Partial α4ß2 nicotinic receptor agonist and α7 full agonist |
|
| DCC5383 | Variegatic Acid | Natural inhibitor of β-hexosaminidase release and tumor necrosis factor (TNF)-α secretion from rat basophilic leukemia (RBL 2H3) cells, with IC50 values of 10.4 μM and 16.8 μM, respectively, also inhibiting PKC β1 activity with an IC50 value of 36.2 μM |
|
| DCC5385 | Vb-703 | Novel potent TLR‐4 activation inhibitor, attenuating the expression of fibrosis hallmark genes collagen, fibronectin (FN) and transforming growth factor β (TGF‐β) in kidneys and improved albumin/creatinine ratio with higher efficacy |
|
| DCC5386 | Vbit-12 | Novel potent inhibitor of VDAC1, directly interacting with purified VDAC1 and reducing its channel conductance |
|
| DCC5387 | Vbit-3 | Novel inhibitor of VDAC1 oligomerization and apoptosis |
|
| DCC5388 | Vch-759 | Novel non-nucleoside inhibitor of HCV RNA-dependent polymerase |
|
| DCC5389 | Vchcaγ Inhibitor 40 | Novel selective inhibitor of the γ-class enzyme of bacteria Vibrio cholerae A (VchCAγ) |
|
| DCC5390 | Vd11-4-2 | Novel potent and selective CA IX inhibitor |
|
| DCC5391 | Vd12-09 | Novel potent and selective CA IX inhibitor |
|
| DCC5392 | Vdr Modulator C4 | Novel nonsecosteroidal vitamin D receptor (VDR) modulator, enhancing pancreatic cancer therapy through remodeling of the tumor microenvironment by combination with gemcitabine |
|
| DCC5393 | Vdr Modulator I5 | Novel nonsecosteroidal vitamin D receptor (VDR) modulator, enhancing pancreatic cancer therapy through remodeling of the tumor microenvironment by combination with gemcitabine |
|
| DCC5394 | Vdr Modulator I8 | Novel nonsecosteroidal vitamin D receptor (VDR) modulator, enhancing pancreatic cancer therapy through remodeling of the tumor microenvironment by combination with gemcitabine |
|
| DCC5395 | Ve-465 | Novel Aurora kinase inhibitor |
|
| DCC5396 | Vegfr-in-v | Potent, Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Tyrosine Kinase Inhibitor |
|
| DCC5397 | Veledimex | Activator for Proprietary Gene Therapy Promoter System |
|
| DCC5398 | Venlafaxine | Serotonin-norepinephrine reuptake inhibitor (SNRI); Antidepressant |
|
| DCC5399 | Ver-246608 Featured | Novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupting Warburg metabolism and inducing context-dependent cytostasis in cancer cells |
|
| DCC5400 | veratramine Hydrochloride | Antitumor agent |
|
| DCC5401 | Veratridine | Natural Janus-Faced Modulator of Voltage-Gated Sodium Ion Channels, acting on the channel as either an agonist or antagonist depending on the nature of the electrophysiological stimulation protocol |
|
| DCC5402 | Verminoside | Natural anti-inflammatory and antioxidant agent, inhibiting both iNOS expression and NO release in the LPS-induced J774.A1 macrophage cell line, enhancing protein expression levels of PARP-1 and p53, and attenuating intracellular ROS and stress (oxidative |
|
| DCC5403 | Vernakalant | Novel blocker of atrial potassium channels |
|
| DCC5404 | Vernolepin | Natural Reversible Plant Growth Inhibitor |
|
| DCC5405 | Verticilide | Natural insect ryanodine receptor (RyR) antagonist |
|
| DCC5406 | Verticillin A | Apoptosis inducer, inhibiting Leiomyosarcoma and Malignant peripheral nerve sheath tumor growth |
|
| DCC5407 | Vesamicol Hydrochloride | Potent inhibitor of acetylcholine transport |
|
| DCC5408 | Vesiculopolin B | Novel anti-vesiculoviral agent, inhibiting transcription initiation of vesiculoviruses |
|
| DCC5409 | Vezf1-in-t4 | Novel Inhibitor of the Pro-Angiogenic Activity of the Zinc Finger Transcription Factor Vezf1 |
|
| DCC5410 | Vhl-hif1α Inhibitor-tg0 | The first sub-micromolar inhibitor of the VHL-HIF1α interaction |
|
| DCC5411 | Vibsanin A | Natural protein kinase C (PKC) activator and HSP90 inhibitor, sensitizing human acute myeloid leukemia cells to tyrosine kinase inhibitor-induced myeloid differentiation via activation of PKC and upregulation of Lyn |
|
